Medpace Q3 Revenue Rises 8.5%, Approves $1B Buyback
Medpace reported Q3 2026 revenue of $716.0 million, up 8.5% year over year, and GAAP EPS of $4.84. Backlog increased to $3.17 billion, and the company reaffirmed 2026 revenue guidance of $2.835 billion–$2.855 billion and GAAP net income guidance of $514 million–$524 million.